

Versio 1.4	n Revision Date: 09.04.2021		S Number: 74882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019				
1. PRC	DUCT AND COMPANY ID	ENT	IFICATION					
P	Product name : Loratadine / Montelukast Formulation							
М	Manufacturer or supplier's details							
C	ompany	:	Organon & Co.					
A	ddress	:	30 Hudson Stree Jersey City, New	t, 33nd floor Jersey, U.S.A 07302				
Τe	elephone	:	551-430-6000					
E	mergency telephone numbe	er :	215-631-6999					
E	-mail address	:	EHSSTEWARD	⊉organon.com				
	ecommended use of the c			ons on use				
R	ecommended use	:	Pharmaceutical					
2. HAZ	ARDS IDENTIFICATION							
G	HS Classification							
R	eproductive toxicity	:	Category 2					
	ong-term (chronic) aquatic azard	:	Category 2					
G	HS label elements							
H	azard pictograms	:		¥				
Si	ignal word	:	Warning	V				
H	azard statements	:		l of damaging fertility. Juatic life with long lasting effects.				
Pi	recautionary statements	:	P202 Do not han and understood. P273 Avoid relea P280 Wear protect tion/ face protect Response:	exposed or concerned: Get medical advice/				



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020	
1.4	09.04.2021	4574882-00005	Date of first issue: 08.07.2019	

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form combustible dust concentrations in air during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture

: Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 50
Montelukast	151767-02-1	>= 1 -< 10
Loratadine	79794-75-5	>= 3 -< 10

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Suspected of damaging fertility. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

SAFETY DATA SHEET



Loratadine / Montelukast Formulation

Versior 1.4	١	Revision Date: 09.04.2021		S Number: 74882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019	
Su	Suitable extinguishing media Unsuitable extinguishing media Specific hazards during fire- fighting		:	 Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical None known. Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health 		
			:			
			:			
Ha uc		ous combustion prod-	:	Carbon oxides		
•	Specific extinguishing meth- ods Special protective equipment for firefighters S. ACCIDENTAL RELEASE MEAS Personal precautions, protec- tive equipment and emer- gency procedures		:	cumstances and t Use water spray t Remove undamag so.	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do	
			:		e, wear self-contained breathing apparatus. ective equipment.	
6. ACC			SUF	RES		
tiv			:	Follow safe handl	ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).	
En	iviron	mental precautions	Retain and dispose of con		akage or spillage if safe to do so. se of contaminated wash water. should be advised if significant spillages	
		s and materials for ment and cleaning up	:	tainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the att Local or national posal of this mate employed in the c mine which regula Sections 13 and 1	dust in the air (i.e., clearing dust surfaces	

7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust
		causing an explosion.
		Provide adequate precautions, such as electrical grounding



Version 1.4	Revision Date: 09.04.2021	SDS Number: 4574882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
	al/Total ventilation ce on safe handling	 Use only with a Do not breathe Do not swallow Avoid contact w Avoid prolonge Handle in acco practice, based sessment Minimize dust g Keep container Keep away from Take precautio 	
Con	ditions for safe storage	Store locked up	
Mate	erials to avoid		ance with the particular national regulations. th the following product types: g agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	PEL (long term)	10 mg/m3	SG OEL
		TWA	10 mg/m3	ACGIH
Montelukast	151767-02-1	TWA	40 µg/m3 (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Loratadine	79794-75-5	TWA	40 µg/m3 (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal

Components with workplace control parameters

Engineering measures :	All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con- tainment devices). Minimize open handling.	
Personal protective equipment		
Respiratory protection :	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.	
Filter type :	Particulates type	

Material : Chemical-resistant gloves

Hand protection



Version 1.4	Revision Date: 09.04.2021	SDS Number: 4574882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019			
	emarks protection	: Wear safety g If the work en mists or aeros Wear a facesl	 Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols 			
Skin :	and body protection	 Work uniform or laboratory coat. Additional body garments should be used based upon th task being performed (e.g., sleevelets, apron, gauntlets, posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove poter contaminated clothing. 				
Hygiene measures		eye flushing s ing place. When using d Wash contam The effective engineering c appropriate de industrial hygi	 If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work- ing place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 			

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	tablet
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form combustible dust concentrations in air during pro- cessing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

SAFETY DATA SHEET



Loratadine / Montelukast Formulation

Ver 1.4	sion	Revision Date: 09.04.2021		S Number: 74882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
	Vapour pressure		:	Not applicable	
	Relative vapour density		:	Not applicable	
	Relative	e density	:	No data available	9
	Density	,	:	No data available	9
	Solubility(ies) Water solubility		:	No data available	9
	Partition coefficient: n- octanol/water Auto-ignition temperature Decomposition temperature		:	Not applicable	
			:	No data available	9
			:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	Not applicable	
	Explosi	ve properties	:	Not explosive	
	.				
	Oxidizir	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	9
	Particle	e size	:	No data available	9

10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	: :	Not classified as a reactivity hazard. Stable under normal conditions. May form combustible dust concentrations in air during pro- cessing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.



Version 1.4	Revision Date: 09.04.2021	SDS Number: 4574882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019			
<u>Co</u>	mponents:					
Ce	llulose:					
Aci	ute oral toxicity	: LD50 (Rat): >	5,000 mg/kg			
Ac	ute inhalation toxicity	Exposure time	: LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist			
Aci	ute dermal toxicity	: LD50 (Rabbit)	z > 2,000 mg/kg			
Мо	ntelukast:					
Aci	ute oral toxicity	: LD50 (Rat): >	5,000 mg/kg			
		LD50 (Mouse)	: > 5,000 mg/kg			
Aci	ute inhalation toxicity	: Remarks: No o	data available			
Ac	ute dermal toxicity	: Remarks: No o	data available			
Lo	ratadine:					
Acı	ute oral toxicity	: LD50 (Rat): >	5,000 mg/kg			
Ас	ute inhalation toxicity	: LC50 (Rat): > Exposure time Test atmosphe Assessment: 1 tion toxicity	:1h	-		

Skin corrosion/irritation

Not classified based on available information.

Components:

Montelukast:

Species Result		Rabbit Mild skin irritation
-------------------	--	--------------------------------

Loratadine:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Montelukast:

Species	:	Rabbit
Result	:	Severe irritation



Revision Date: 09.04.2021			Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
adine:			
es	:	Rabbit	
	:		
		·	
-	sitisatio	n	
ensitisation			
assified based on av	vailable	information.	
ratory sensitisatio	n		
-		information.	
onents:			
		No doto ovoilabl	
IKS	•	NO Gala availabi	e
adine:			
уре	:	Maximisation Te	st
ure routes	:	Dermal	
es	:	Guinea pig	
	:		skin sensitisation.
	:	negative	
cell mutagenicity assified based on av	vailable	information.	
	vailable	information.	
assified based on av	ailable	information.	
assified based on av onents: ose:	vailable :		erial reverse mutation assay (AMES)
assified based on av onents:	vailable :		erial reverse mutation assay (AMES)
assified based on av onents: ose:	vailable :	Test Type: Bacte Result: negative	
assified based on av onents: ose:	vailable :	Test Type: Bacte Result: negative Test Type: In vit	erial reverse mutation assay (AMES) ro mammalian cell gene mutation test
assified based on av onents: ose: oxicity in vitro	vailable :	Test Type: Bacte Result: negative Test Type: In vit Result: negative	ro mammalian cell gene mutation test
assified based on av onents: ose:	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo
assified based on av onents: ose: oxicity in vitro	vailable :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo
assified based on av onents: ose: oxicity in vitro	vailable :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo y)
assified based on av onents: ose: oxicity in vitro	vailable :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo y)
assified based on av onents: ose: oxicity in vitro	vailable :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo y)
assified based on av onents: ose: oxicity in vitro oxicity in vivo	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo ay) e: Ingestion
assified based on av onents: ose: oxicity in vitro	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo y)
assified based on av onents: ose: oxicity in vitro oxicity in vivo	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative Test Type: Bacte Result: negative	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo ay) e: Ingestion erial reverse mutation assay (AMES)
assified based on av onents: ose: oxicity in vitro oxicity in vivo	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative Test Type: Bacte Result: negative Test Type: In vit	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo ay) e: Ingestion erial reverse mutation assay (AMES) ro mammalian cell gene mutation test
assified based on av onents: ose: oxicity in vitro oxicity in vivo	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative Test Type: Bacte Result: negative Test Type: In vit	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo ay) e: Ingestion erial reverse mutation assay (AMES)
assified based on av onents: ose: oxicity in vitro oxicity in vivo	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative Test Type: Bacte Result: negative Test Type: In vit Test Type: In vit Result: negative	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo y) e: Ingestion erial reverse mutation assay (AMES) ro mammalian cell gene mutation test inese hamster fibroblasts
assified based on av onents: ose: oxicity in vitro oxicity in vivo	vailable : :	Test Type: Bacte Result: negative Test Type: In vit Result: negative Test Type: Mam cytogenetic assa Species: Mouse Application Rout Result: negative Test Type: Bacte Result: negative Test Type: In vit Test system: Ch Result: negative Test Type: Chro	ro mammalian cell gene mutation test malian erythrocyte micronucleus test (in vivo ay) e: Ingestion erial reverse mutation assay (AMES) ro mammalian cell gene mutation test
	09.04.2021 adine: assiried based on averatory sensitisation assified based on averatory sensitisation assif	09.04.2021 45 adine: assified based on available ratory sensitisation assified based on available ratory sensitisation assified based on available onents: elukast: rks assiment	09.04.2021 4574882-00005 adine:



ersion 1	Revision Date: 09.04.2021		S Number: 74882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
			Test Type: Alkal Test system: rat Result: negative	
Geno	toxicity in vivo	:	Test Type: Chro Species: Mouse Cell type: Bone Application Rou Result: negative	marrow te: Oral
Lorat	adine:			
Geno	toxicity in vitro	:	Test Type: Bact Result: negative	erial reverse mutation assay (AMES)
			Test Type: In vit Result: negative	ro mammalian cell gene mutation test
			Test Type: Chro Result: negative	mosome aberration test in vitro
				damage and repair, unscheduled DNA syn- alian cells (in vitro)
Geno	toxicity in vivo	:	Test Type: Micro Species: Mouse Cell type: Bone Application Rou Result: negative	marrow te: Oral
	cell mutagenicity -	:	Weight of evider cell mutagen.	nce does not support classification as a germ
Not cl <u>Com</u> t	nogenicity lassified based on ava ponents:	ailable	information.	
Cellu			Det	
Speci Applic	es cation Route	:	Rat Ingestion	
Expos	sure time	:	72 weeks	
Resul	lt	:	negative	
Monte	elukast:			
Speci		:	Rat	
	cation Route sure time	:	Oral 2 Years	
Resul		:	negative	
Speci	es	:	Mouse	
	cation Route		Oral	



rsion I	Revision Date: 09.04.2021	SDS Number:Date of last issue: 10.10.20204574882-00005Date of first issue: 08.07.2019	
Expo Resu	sure time It	: 92 weeks : negative	
Lora	tadine:		
	cation Route sure time EL	 Rat Oral 2 Years 10 mg/kg body weight positive 	
Spec Appli	ies cation Route sure time EL	 Monkey Oral 17 Months 40 mg/kg body weight negative 	
•	oductive toxicity ected of damaging ferti	ty.	
<u>Com</u>	ponents:		
	Ilose: ts on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative	
Effec ment	ts on foetal develop-	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative	
Mont	telukast:		
	ts on fertility	: Test Type: Fertility Species: Rat, male Application Route: Oral Fertility: NOAEL: 800 mg/kg body weight Result: Animal testing did not show any effects on fertili	ty.
		Test Type: Fertility Species: Rat, female Application Route: Oral Fertility: LOAEL: 200 mg/kg body weight Symptoms: Reduced fertility	
		Test Type: Fertility Species: Rat, female Application Route: Oral Fertility: NOAEL: 100 mg/kg body weight Symptoms: Reduced fertility	

Loratadine:



4	Revision Date: 09.04.2021	SDS Num 4574882-	
Effec	ts on fertility	Applic Fertilit	es: Rat, male cation Route: Oral ty: LOAEL: 64 mg/kg body weight t: Effects on fertility
Effec ment	ts on foetal develop-	Applic Devel	es: Rat cation Route: Oral opmental Toxicity: LOAEL: 48 mg/kg body weight t: Embryo-foetal toxicity
		Applic Devel	es: Rabbit cation Route: Oral opmental Toxicity: LOAEL: 48 mg/kg body weight t: Embryo-foetal toxicity
		Applic	es: Rat cation Route: Oral opmental Toxicity: LOAEL: 12 mg/kg body weight
Repro sessr	oductive toxicity - As- nent		e evidence of adverse effects on sexual function and y, based on animal experiments.
	Γ - repeated exposure lassified based on avai	lable informa	ation.
_			
-	eated dose toxicity		
Com	ponents:		
Com Cellu Spec NOA Appli	ponents: llose: ies	: Rat : >= 9,0 : Ingest : 90 Da	
Com Cellu Spec NOA Appli Expo	ponents: llose: ies EL cation Route sure time	: >= 9,0 : Ingest	tion
Com Cellu Spec NOA Appli Expo Mont Spec NOA Appli	ponents: lose: ies EL cation Route sure time relukast: ies EL cation Route sure time	: >= 9,0 : Ingest : 90 Da : Monke : 150 - : Oral : 53 We	tion iys ey, male and female 300 mg/kg
Com Cellu Spec NOAI Appli Expo Mont Spec NOAI Appli Expo Rema	ponents: lose: ies EL cation Route sure time relukast: ies EL cation Route sure time arks ies EL cation Route sure time arks	 >= 9,0 Ingest 90 Da 90 Da 150 - Oral 53 We No sig Rat 50 mg Oral 53 We 	tion nys ey, male and female 300 mg/kg eeks gnificant adverse effects were reported g/kg



rsion L	Revision Date: 09.04.2021	SDS Number: 4574882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019					
	sure time	: 14 Weeks						
Rema	ırks	: No significant	adverse effects were reported					
Lorat	adine:							
Speci	es	: Rat						
NOAEL LOAEL Application Route		: 4 mg/kg						
		: 8 mg/kg						
	sure time		: Oral : 180 Days					
	t Organs	: Central nervou	is system					
Rema			limited toxicological significance.					
Speci	es	: Monkey						
NOAE		: 0.4 mg/kg						
LOAE		: 4 mg/kg						
	cation Route	: Oral						
	sure time et Organs	: 180 Days : Central nervou	is system					
Rema			limited toxicological significance.					
Not cl Expe	ation toxicity assified based on av rience with human o ponents:							
Not cl Exper Comr Monte Skin c	assified based on av rience with human e ponents: elukast: contact ontact	exposure : Remarks: May : Symptoms: Se : Symptoms: up						
Not cl Exper Comp Monte Skin c Eye c Ingest	assified based on av rience with human e ponents: elukast: contact ontact	exposure : Remarks: May : Symptoms: Se : Symptoms: up	evere irritation oper respiratory tract infection, pharyngitis,					
Not cl Exper Comp Monte Skin c Eye c Ingest	assified based on av rience with human of ponents: elukast: contact ontact tion adine:	 Remarks: May Symptoms: Se Symptoms: up Headache, Co 	evere irritation oper respiratory tract infection, pharyngitis,					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT	 Remarks: May Symptoms: Set Symptoms: up Headache, Cot Symptoms: Fa 	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT	 Remarks: May Symptoms: Set Symptoms: up Headache, Cot Symptoms: Fa 	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents:	 Remarks: May Symptoms: Set Symptoms: up Headache, Cot Symptoms: Fa 	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO Ecoto Comp Cellul	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents: lose:	Exposure : Remarks: May : Symptoms: Se : Symptoms: up Headache, Co : Symptoms: Fa TON	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever atigue, Headache, dry mouth, Nausea					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO Ecoto Comp Cellul	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents:	 Exposure Remarks: May Symptoms: Se Symptoms: up Headache, Co Symptoms: Fa TON LC50 (Oryzias Exposure time 	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever atigue, Headache, dry mouth, Nausea					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO Ecoto Comp Cellul Toxici	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents: lose:	 Exposure Remarks: May Symptoms: Se Symptoms: up Headache, Co Symptoms: Fa TON LC50 (Oryzias Exposure time 	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever atigue, Headache, dry mouth, Nausea					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO Ecoto Comp Cellul Toxici	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents: lose: ity to fish	 Remarks: May Symptoms: Se Symptoms: up Headache, Co Symptoms: Fa 'ION LC50 (Oryzias Exposure time Remarks: Bas	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever atigue, Headache, dry mouth, Nausea s latipes (Japanese medaka)): > 100 mg/l e: 48 h sed on data from similar materials					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO Ecoto Comp Cellul Toxici	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents: lose: ity to fish	 Remarks: May Symptoms: Set Symptoms: up Headache, Co Symptoms: Fa TON LC50 (Oryzias Exposure time Remarks: Bas LC50 (Pimeph Exposure time 	evere irritation oper respiratory tract infection, pharyngitis, bugh, Abdominal pain, Diarrhoea, Fever atigue, Headache, dry mouth, Nausea atigue, Headache, dry mouth, Nausea					
Not cl Exper Comp Monte Skin c Eye c Ingest Lorat Ingest . ECOLO Ecoto Comp Cellul Toxici	assified based on av rience with human of ponents: elukast: contact ontact tion adine: tion OGICAL INFORMAT oxicity ponents: lose: ity to fish	 Remarks: May Symptoms: See Symptoms: up Headache, Co Symptoms: Fa TON LC50 (Oryzias Exposure time Remarks: Bas LC50 (Pimeph Exposure time Method: OECI 	evere irritation oper respiratory tract infection, pharyngitis, ough, Abdominal pain, Diarrhoea, Fever atigue, Headache, dry mouth, Nausea e latipes (Japanese medaka)): > 100 mg/l e: 48 h sed on data from similar materials nales promelas (fathead minnow)): > 0.0778 mg					



Vers 1.4	sion	Revision Date: 09.04.2021		S Number: 74882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
	Toxicity to daphnia and other aquatic invertebrates		:	Exposure time: 48 Method: OECD Te	
	Toxicity plants	to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD Te	
					est Guideline 201
	Toxicity icity)	to fish (Chronic tox-	:	Exposure time: 32 Method: OECD Te	
				mg/l Exposure time: 7	on variegatus (sheepshead minnow)): 0.0816 d city at the limit of solubility
		to daphnia and other invertebrates (Chron- ty)	:	Exposure time: 21	nagna (Water flea)): 0.23 mg/l d city at the limit of solubility
	Toxicity	to microorganisms	:	EC50: > 100 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te Remarks: No toxic	ation inhibition
	Lorata	dine:			
	Loratadine: Toxicity to fish		:	LC50 (Lepomis m Exposure time: 96 Method: OECD Te	
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
	Toxicity plants	v to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te	
				NOEC (Pseudokir mg/l Exposure time: 72	chneriella subcapitata (green algae)): 0.053 ? h



ersion 4	Revision Date: 09.04.2021		S Number: 74882-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019		
			Method: OECD	Test Guideline 201		
M-Fact icity)	or (Acute aquatic tox-	:	1			
Toxicity to fish (Chronic tox- icity)		:	: NOEC (Pimephales promelas (fathead minnow)): 0.084 mg/ Exposure time: 32 d Method: OECD Test Guideline 210			
	v to daphnia and other invertebrates (Chron- ity)	:	NOEC (Daphnia magna (Water flea)): 0.078 mg/l Exposure time: 21 d Method: OECD Test Guideline 211			
M-Fact toxicity	or (Chronic aquatic	:	1			
	oxicity to microorganisms		EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209			
Persist	ence and degradabili	ity				
Compo	onents:					
Cellulo Biodeg	se: radability	:	Result: Readily	biodegradable.		
Montel	ukast:					
Biodeg	radability	:	Result: not rapid Biodegradation: Exposure time:	0 %		
Stability	y in water	:	Hydrolysis: 50 %	%(21.7 h)		
Lorata	dine:					
Biodeg	radability	:	Result: not rapid Biodegradation: Exposure time: Method: OECD	50 %		
Stability	y in water	:	Degradation ha	lf life (DT50): 283 d		
Bioacc	umulative potential					
Compo	onents:					
Montel Partitio octanol	n coefficient: n-	:	log Pow: > 4.3			
Lorata	dine: n coefficient: n-	:	log Pow: 2.35			



Version 1.4	Revision Date: 09.04.2021	SDS Number:Date of last issue: 10.10.20204574882-00005Date of first issue: 08.07.2019		
Mobi	lity in soil			
Com	ponents:			
Distril	adine: bution among environ- al compartments	: log Koc: 5.25 Method: OECD Test Guideline 106		
	r adverse effects ata available			
13. DISPC	SAL CONSIDERATION	15		
Waste	osal methods e from residues aminated packaging	 Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. 		
14. TRAN	SPORT INFORMATION	 		
Interr	national Regulations			
	TDG umber er shipping name	 UN 3077 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Loratadine) 		
Class Packi Label	ng group	: 9 : III : 9		
IATA UN/IE Prope	-	 UN 3077 Environmentally hazardous substance, solid, n.o.s. 		
Label Packi aircra	ng group s ng instruction (cargo	(Loratadine) : 9 : III : Miscellaneous : 956 : 956		
ger ai	ircraft) onmentally hazardous	: yes		
IMDG UN ni	G-Code umber er shipping name	 : UN 3077 : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Loratadine) 		
Label EmS	ng group	(Loratadine) 9 III 9 F-A, S-F yes		



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.4	09.04.2021	4574882-00005	Date of first issue: 08.07.2019

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazard- ous Substances) Regulations	:	Not applicable	
Fire Safety (Petroleum and Flammable Materials)	:	Not applicable	

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Regulations

Further information Sources of key data used to compile the Safety Data Sheet	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/			
Date format	dd.mm.yyyy			
Full text of other abbreviations				
ACGIH SG OEL	USA. ACGIH Threshold Limit Values (TLV) Singapore. Workplace Safety and Health Act - First Schedule Permissible Exposure Limits of Toxic Substances			
ACGIH / TWA SG OEL / PEL (long term)	8-hour, time-weighted average Permissible Exposure Level (PEL) Long Term			

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -



Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.4	09.04.2021	4574882-00005	Date of first issue: 08.07.2019

Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN